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Background
Th1/Tr1 promoting adjuvants, in allergen-specific vac-
cines, could be a valuable alternative to the current aller-
gen immunotherapy. It is now the pro-Th1 adjuvant effect
of Neisseria meningitidis proteoliposome (PL). Previous
studies in a prophylactic murine model of respiratory
allergy the vaccine showed its immunogenicity and safety.
To assess the immunogenicity and non-clinical safety pro-
file of a novel anti-allergic vaccine candidate based on pur-
ified allergens from Dermatophagoides siboney and a
combination adjuvant containing PL and Alum, in sensi-
tized mice.
Methods
In therapeutic experimental setting C57/Bl6 mice were first
sensitized administering D. siboney allergen by IP route
and exposing mice to allergen aerosols. Later, allergic mice
were treated with 3 doses of the adjuvanted vaccine (2µg of
Der s1) by subcutaneous route. Further, mice were sub-
jected to inhalation allergen challenge. IgE, IgG1, and
IgG2a allergen-specific antibody response was measured by
ELISA. The specific cellular response (IL-13, IL-10 and
INF-g), were evaluated in supernatants of Lymphocyte cul-
tures stimulated with the allergen, by eBioscience kit for
FACS. Systemic toxicity was assessed measuring body
weight and macroscopic and histological examination of
several organs and injection site.
Results
The experimental model reproduces the allergic condi-
tion with allergen-specific IgE production; increased
blood eosinophils and Histology of lung tissues show all
the characteristic of allergy inflammation. As in the pre-
viously tested preventive model, the vaccine induces a
strong IgG and IgG1 antibody responses significantly
higher than control groups, and moderate levels of IFN-
g, although together with Tr1 (IL-10) and Th2 (Il-13)
cytokines. After challenge, it was noted a significant
increase (p<0.05) of the IgG/IgE ratio, with a decrease
in bloods eosinophils and allergic inflammation in lung
tissues as compared to placebo. No significant differ-
ences between body weights and differential leukocyte
count in treated mice and placebo group was observed.
Normal histology was observed. Local tolerance at the
injection site suggests that granulomes in vaccinated
subjects are caused by alum.
Conclusions
The adjuvanted vaccine does not exacerbate the allergic
response nor promote Th1 inflammation, supporting a
satisfactory safety profile for further clinical trials in
humans. This immunomodulatory effect suggests clinical
benefits both in cellular and blocking antibody responses.
Published: 23 April 2013
doi:10.1186/1939-4551-6-S1-P151
Cite this article as: González: Immunotherapy – 2068.
Immunomodulatory and safety profile of a novel anti-allergic vaccine
based on allergens from dermatophagoides siboney and a combination
adjuvant, in sensitized mice. World Allergy Organization Journal 2013
6(Suppl 1):P151.
Allergens Laboratory, National Center of Bioproducts, Mayabeque, Cuba
González World Allergy Organization Journal 2013, 6(Suppl 1):P151
http://www.waojournal.org/content/6/S1/P151
© 2013 González; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
